TY - JOUR T1 - Combined <sup>18</sup>F-Fluoride and <sup>18</sup>F-FDG PET/CT Scanning for Evaluation of Malignancy: Results of an International Multicenter Trial JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 176 LP - 183 DO - 10.2967/jnumed.112.108803 VL - 54 IS - 2 AU - Andrei Iagaru AU - Erik Mittra AU - Camila Mosci AU - David W. Dick AU - Mike Sathekge AU - Vineet Prakash AU - Victor Iyer AU - Paula Lapa AU - Jorge Isidoro AU - Joao M. de Lima AU - Sanjiv Sam Gambhir Y1 - 2013/02/01 UR - http://jnm.snmjournals.org/content/54/2/176.abstract N2 - 18F-FDG PET/CT is used in a variety of cancers, but because of variable rates of glucose metabolism, not all cancers are reliably identified. 18F− PET/CT allows for the acquisition of highly sensitive and specific images of the skeleton. We prospectively evaluated combined 18F−/18F-FDG as a single PET/CT examination for evaluation of cancer patients and compared it with separate 18F− PET/CT and 18F-FDG PET/CT scans. Methods: One hundred fifteen participants with cancer were prospectively enrolled in an international multicenter trial evaluating 18F− PET/CT, 18F-FDG PET/CT, and combined 18F−/18F-FDG PET/CT. The 3 PET/CT scans were performed sequentially within 4 wk of one another for each patient. Results: 18F−/18F-FDG PET/CT allowed for accurate interpretation of radiotracer uptake outside the skeleton, with findings similar to those of 18F-FDG PET/CT. In 19 participants, skeletal disease was more extensive on 18F− PET/CT and 18F−/18F-FDG PET/CT than on 18F-FDG PET/CT. In another 29 participants, 18F− PET/CT and 18F−/18F-FDG PET/CT showed osseous metastases where 18F-FDG PET/CT was negative. The extent of skeletal lesions was similar in 18 participants on all 3 scans. Conclusion: This trial demonstrated that combined 18F−/18F-FDG PET/CT shows promising results when compared with separate 18F− PET/CT and 18F-FDG PET/CT for evaluation of cancer patients. This result opens the possibility for improved patient care and reduction in health-care costs, as will be further evaluated in future trials. ER -